Ozempic vs Mounjaro: Full Comparison (2026)

How They Work: Single vs Dual Agonist

The most important difference between Ozempic and Mounjaro is their mechanism of action. Understanding this helps explain why clinical outcomes differ.

Ozempic (semaglutide)is a GLP-1 receptor agonist. It mimics the GLP-1 hormone, which your body produces after eating. GLP-1 slows gastric emptying (so you feel full longer), reduces appetite by acting on the brain's hunger centers, and stimulates insulin release while suppressing glucagon to lower blood sugar.

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist — the first in its class. In addition to all the GLP-1 effects above, it also activates the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP enhances insulin secretion, improves fat metabolism, and may have additional effects on appetite regulation and energy expenditure that complement GLP-1 activity.

Think of it this way: Ozempic pulls one lever to reduce appetite and improve metabolism. Mounjaro pulls two levers simultaneously. This dual mechanism appears to produce a synergistic effect — the combined GLP-1 and GIP activation is greater than what either hormone achieves alone.

FDA Approval Status

Both Ozempic and Mounjaro are FDA-approved for type 2 diabetes, not weight loss. However, both are widely prescribed off-label for weight management, and both have weight-loss-specific sister products:

• Ozempic (semaglutide) — approved December 2017 for type 2 diabetes. Its weight loss counterpart is Wegovy (semaglutide 2.4mg), approved June 2021 for chronic weight management.
• Mounjaro (tirzepatide) — approved May 2022 for type 2 diabetes. Its weight loss counterpart is Zepbound (tirzepatide), approved November 2023 for chronic weight management.

If your primary goal is weight loss and you do not have type 2 diabetes, your doctor may prescribe either Ozempic or Mounjaro off-label, or prescribe the weight-loss-approved versions (Wegovy or Zepbound) for on-label use. The on-label weight loss drugs tend to have better insurance coverage for weight management.

One significant difference: semaglutide (Ozempic/Wegovy) has proven cardiovascular benefit from the SELECT trial, earning Wegovy a cardiovascular risk reduction indication. Tirzepatide (Mounjaro/Zepbound) is still being evaluated in the SURPASS-CVOT trial, with results expected in 2026-2027. Early signals are promising, but the cardiovascular benefit is not yet confirmed.

Blood Sugar Control

For patients with type 2 diabetes, blood sugar control (measured by A1C) is a primary treatment goal. Both medications are highly effective, but Mounjaro shows a consistent edge:

• Ozempic reduces A1C by approximately 1.0-1.8 percentage points depending on dose (SUSTAIN trials). At the 1mg dose, average A1C reduction was 1.5-1.8%.
• Mounjaro reduces A1C by approximately 1.9-2.4 percentage points (SURPASS trials). At the 15mg dose, average A1C reduction was up to 2.4%.

In the head-to-head SURPASS-2 trial, all three Mounjaro doses (5mg, 10mg, 15mg) were superior to Ozempic 1mg for A1C reduction. The highest Mounjaro dose achieved an average A1C of 5.5% — below the diabetes diagnostic threshold of 6.5% — meaning many patients effectively achieved diabetes remission.

However, it is important to note that SURPASS-2 compared Mounjaro against the 1mg dose of semaglutide, not the 2mg dose. The 2mg Ozempic dose, approved later, closes the gap somewhat but still appears to produce less A1C reduction than the higher Mounjaro doses based on cross-trial comparison.

Side Effects Comparison

Ozempic and Mounjaro share a similar side effect profile because both activate the GLP-1 receptor. Gastrointestinal symptoms are the most common side effects for both medications.

Common Side Effects

Overall, the GI side effect rates are comparable. Mounjaro may cause slightly more diarrhea and slightly less nausea compared to Ozempic, though differences are small and vary across studies. Both medications see the highest side effect rates during dose escalation, with symptoms typically improving at steady-state doses.

The dropout rate due to side effects in clinical trials was similar for both: roughly 4-7% of participants discontinued due to adverse events. This is considered low for medications with these types of GI effects.

Serious Risks

Both medications carry similar warnings including thyroid C-cell tumor risk (boxed warning based on animal data), pancreatitis, gallbladder disease, and acute kidney injury. Neither should be used in patients with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Cost and Insurance

Without insurance, Ozempic and Mounjaro are priced similarly:

• Ozempic: approximately $998 per month (list price)
• Mounjaro: approximately $1,023 per month (list price)

Insurance coverage varies by plan and diagnosis:

• With type 2 diabetes diagnosis: Both are generally covered by most commercial insurance plans. Copays typically range from $25-$150/month after prior authorization.
• For weight loss (off-label): Coverage is inconsistent. Some plans cover off-label use, others require the weight-loss-specific versions (Wegovy or Zepbound). Coverage for anti-obesity medications has been expanding in 2025-2026.
• Medicare: Both are covered under Part D for diabetes. Weight loss coverage begins July 1, 2026 through the Medicare GLP-1 Bridge program at $50/month.

Savings Programs

Both manufacturers offer copay savings cards for commercially insured patients:

• Ozempic Savings Card: Copay as low as $25/month for up to 24 months
• Mounjaro Savings Card: Copay as low as $25/month for up to 12 months

If you are paying out of pocket without insurance, consider the weight-loss-approved versions: Oral Wegovy starts at $149/month, and Zepbound has a direct-to-patient program. See our cheapest GLP-1 programs guide for a full breakdown.